The evolving role of dendritic cell therapy in urologic oncology.
The recognition that dendritic cells, the most potent antigen-presenting cells, play a pivotal role in the induction of antitumor immunity has reshaped the development of tumor vaccines in clinical medicine. Early clinical trials of administration of dendritic cell-based vaccines to patients with genitourinary malignancies showed low toxicity profiles, and provided evidence for immunologic and clinical responses in some patients. Although the development of dendritic cell-based vaccines is still in its infancy, the prospects of ultimately generating clinically effective cancer vaccines have become more realistic.
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA. viewe001@mc.duke.edu
J
J
Vieweg
D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D003713:Dendritic Cells; D006801:Humans; D014571:Urologic Neoplasms / Q000517:prevention & control*
D019496:Cancer Vaccines